A Phase I Bioavailability and Pharmacokinetic Study of [14C]-Ipatasertib Single Oral and Intravenous Doses in Healthy Male Subjects

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

March 31, 2015

Primary Completion Date

April 30, 2015

Study Completion Date

April 30, 2015

Conditions

Healthy Volunteer

Interventions

DRUG

Period 1 treatment

200 mg oral ipatasertib followed 1 hour later by 80-mcg/800-nCi intravenous \[14C\]-ipatasertib on Day 1 of study

DRUG

Period 2 treatment

200-mg/100-mcCi oral \[14C\]-ipatasertib on Day 15 of study

Trial Locations (1)

Madison